We're sorry you missed the webinar. You can still see a recording by filling out the form below.Gain Access
This site uses features not supported by Internet Explorer.
Zostavax is a vaccine for shingles manufactured by the pharmaceutical company Merck, and approved by the U.S. Food and Drug Administration in 2006. It was designed to reduce the risk of getting herpes zoster – a painful and debilitating condition commonly known as “shingles” - in individuals ages 50 years and older.
It was the only approved shingles vaccine in the United States until late 2017, and has been administered more than 36 million times in the last 10 years. It has earned billions of dollars for Merck in the last decade, with $749 million coming in just 2016.